Literature DB >> 22946750

A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma.

Angela V D'Elia1, Franco Grimaldi, Stefano Pizzolitto, Giovanna De Maglio, Elisa Bregant, Nadia Passon, Alessandra Franzoni, Antonella Verrienti, Giulia Tamburrano, Cosimo Durante, Sebastiano Filetti, Federico Fogolari, Diego Russo, Giuseppe Damante.   

Abstract

CONTEXT: Germline mutations in four genes (RET, VHL, SDHB and SDHD) are detected in about 17% of patients with apparently sporadic pheochromocytoma. Thus, genetic screening of all patients with this disease is suggested for a rational diagnostic approach and management.
OBJECTIVE: To report the clinical, biochemical and genetic analysis of three unrelated patients affected by pheochromocytoma. DESIGN AND PATIENTS: All the coding regions and exon-intron boundaries of RET, VHL, SDHB and SDHD genes were sequenced in three unrelated patients with intra-adrenal pheochromocytoma: a 17-year-old girl, a 15-year-old boy and a 73-year-old man. The family history of all three cases was negative for von Hippel-Lindau lesions or other types of endocrine tumours. Structural modelling of the VHL protein was then performed.
RESULTS: We identified a novel germline VHL gene point mutation, a G to A nucleotide substitution in exon 3, leading to an aspartate to asparagine amino acid change in codon 197 (D197N). No mutations were found in RET, SDHB and SDHD genes. Structural modelling of the VHL protein suggests that the D197N mutation could have a functional role.
CONCLUSIONS: Our study expands the number of VHL gene known mutations and indicates the usefulness of performing the genetic analysis in all patients with apparently sporadic pheochromocytoma.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22946750     DOI: 10.1111/cen.12032

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

1.  Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome.

Authors:  Paola Izzo; Marina De Rosa; Lorella Paparo; Giovanni Battista Rossi; Paolo Delrio; Daniela Rega; Francesca Duraturo; Raffaella Liccardo; Mario Debellis
Journal:  Hered Cancer Clin Pract       Date:  2013-07-25       Impact factor: 2.857

2.  An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.

Authors:  Lucy Gossage; Douglas E V Pires; Álvaro Olivera-Nappa; Juan Asenjo; Mark Bycroft; Tom L Blundell; Tim Eisen
Journal:  Hum Mol Genet       Date:  2014-06-26       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.